Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Gu B, Shang X, Yan M, Li X, Wang W, Wang Q, Zhang C. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019. Gynecol Oncol. 2021;161(2):573–80.

Article  PubMed  Google Scholar 

Dubil EA, Tian C, Wang G, Tarney CM, Bateman NW, Levine DA, Conrads TP, Hamilton CA, Maxwell GL, Darcy KM. Racial disparities in molecular subtypes of endometrial cancer. Gynecol Oncol. 2018;149(1):106–16.

Article  PubMed  Google Scholar 

Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412–28.

Article  PubMed  Google Scholar 

Mandal J, Mandal P, Wang TL, Shih IM. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. J Biomed Sci. 2022;29(1):71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov. 2013;3(1):35–43.

Article  CAS  PubMed  Google Scholar 

Wang L, Qu J, Zhou N, Hou H, Jiang M, Zhang X. Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers. Biomed Pharmacother. 2020;130:110626.

Article  CAS  PubMed  Google Scholar 

Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, Crabtree GR. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013;45(6):592–601.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495–501.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang GG, Allis CD, Chi P. Chromatin remodeling and cancer, Part II: ATP-dependent chromatin remodeling. Trends Mol Med. 2007;13(9):373–80.

Article  PubMed  PubMed Central  Google Scholar 

Mao TL, Ardighieri L, Ayhan A, Kuo KT, Wu CH, Wang TL, Shih IM. Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. Am J Surg Pathol. 2013;37(9):1342–8.

Article  PubMed  PubMed Central  Google Scholar 

Kelso TWR, Porter DK, Amaral ML, Shokhirev MN, Benner C, Hargreaves DC. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers. Elife. 2017. https://doi.org/10.7554/eLife.30506.

Article  PubMed  PubMed Central  Google Scholar 

Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih IM, Conejo-Garcia JR, Speicher DW, Zhang R. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med. 2015;21(3):231–8.

Article  CAS  PubMed  Google Scholar 

Ogiwara H, Takahashi K, Sasaki M, Kuroda T, Yoshida H, Watanabe R, Maruyama A, Makinoshima H, Chiwaki F, Sasaki H, Kato T, Okamoto A, Kohno T. Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers. Cancer Cell. 2019;35(2):177-190.e178.

Article  CAS  PubMed  Google Scholar 

Suryo Rahmanto Y, Shen W, Shi X, Chen X, Yu Y, Yu ZC, Miyamoto T, Lee MH, Singh V, Asaka R, Shimberg G, Vitolo MI, Martin SS, Wirtz D, Drapkin R, Xuan J, Wang TL, Shih IM. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. Nat Commun. 2020;11(1):2717.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guan B, Wang TL, Shih IM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71(21):6718–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang FK, Ni QZ, Wang K, Cao HJ, Guan DX, Zhang EB, Ma N, Wang YK, Zheng QW, Xu S, Zhu B, Chen TW, Xia J, Qiu XS, Ding XF, Jiang H, Qiu L, Wang X, Chen W, Cheng SQ, Xie D, Li JJ. Targeting USP9X-AMPK axis in ARID1A-deficient hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol. 2022;14(1):101–27.

Article  PubMed  PubMed Central  Google Scholar 

Suryo RY, Jung JG, Wu RC, Kobayashi Y, Heaphy CM, Meeker AK, Wang TL, Shih IM. Inactivating ARID1A tumor suppressor enhances TERT transcription and maintains telomere length in cancer cells. J Biol Chem. 2016;291(18):9690–9.

Article  Google Scholar 

Trizzino M, Barbieri E, Petracovici A, Wu S, Welsh SA, Owens TA, Licciulli S, Zhang R, Gardini A. The tumor suppressor ARID1A controls global transcription via pausing of RNA polymerase II. Cell Rep. 2018;23(13):3933–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yen TT, Wang TL, Fader AN, Shih IM, Gaillard S. Molecular classification and emerging targeted therapy in endometrial cancer. Int J Gynecol Pathol. 2020;39(1):26–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jones S, Wang TL, Shih IM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330(6001):228–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.

Article  PubMed  Google Scholar 

Dobrzycka B, Terlikowski SJ, Mazurek A, Kowalczuk O, Niklińska W, Chyczewski L, Kulikowski M. Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma. Folia Histochem Cytobiol. 2009;47(1):65–8.

Article  CAS  PubMed  Google Scholar 

Chava S, Gupta R. Identification of the mutational landscape of gynecological malignancies. J Cancer. 2020;11(16):4870–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Samartzis EP, Noske A, Dedes KJ, Fink D, Imesch P. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci. 2013;14(9):18824–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takeda T, Banno K, Okawa R, Yanokura M, Iijima M, Irie-Kunitomi H, Nakamura K, Iida M, Adachi M, Umene K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, Aoki D. ARID1A gene mutation in ovarian and endometrial cancers (Review). Oncol Rep. 2016;35(2):607–13.

Article  CAS  PubMed  Google Scholar 

Isani SS, Rodriguez-Gabin AG, Goldberg GL, Horwitz SB, McDaid HM. Defining optimal combinations of PI3K/Akt/mTOR and Ras/Raf/MAPK pathway inhibitors for use in endometrial cancer. Gynecol Oncol. 2014;133:127–8.

Article  Google Scholar 

Mandal JP, Shiue CN, Chen YC, Lee MC, Yang HH, Chang HH, Hu CT, Liao PC, Hui LC, You RI, Wu WS. PKCδ mediates mitochondrial ROS generation and oxidation of HSP60 to relieve RKIP inhibition on MAPK pathway for HCC progression. Free Radic Biol Med. 2021;163:69–87.

Article  CAS  PubMed  Google Scholar 

Zandi Z, Kashani B, Alishahi Z, Pourbagheri-Sigaroodi A, Esmaeili F, Ghaffari SH, Bashash D, Momeny M. Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance. J Cancer Res Clin Oncol. 2022;148(1):57–70.

Article  PubMed  Google Scholar 

Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS, Arteaga CL. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res. 2013;73(20):6346–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ito T, Young MJ, Li R, Jain S, Wernitznig A, Krill-Burger JM, Lemke CT, Monducci D, Rodriguez DJ, Chang L, Dutta S, Pal D, Paolella BR, Rothberg MV, Root DE, Johannessen CM, Parida L, Getz G, Vazquez F, Doench JG, Zamanighomi M, Sellers WR. Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. Nat Genet. 2021;53(12):1664–72.

Article  CAS  PubMed  Google Scholar 

Bang S, Jee S, Kim H, Jang K, Park H, Myung JK, Choi D, Shin SJ, Paik SS. Low DUSP4 expression is associated with aggressive phenotypes and poor prognosis in gastric cancer. In Vivo. 2021;35(1):131–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saigusa S, Inoue Y, Tanaka K, Toiyama Y, Okugawa Y, Shimura T, Hiro J, Uchida K, Mohri Y, Kusunoki M. Decreased expression of DUSP4 is associated with liver and lung metastases in colorectal cancer. Med Oncol. 2013;30(3):620.

Article  PubMed  Google Scholar